Fig. 5From: Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trialsSerious systemic adverse events comparing bevacizumab with ranibizumab at 1 year. M-H, Mantel–Haenszel statisticsBack to article page